Compare Iron Mountain Inc (IRM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Sana Biotechnology Inc — how do they compare? Iron Mountain Inc trades at $115.01 (market cap $34.46B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Iron Mountain Inc is far larger — about 41.2× Sana Biotechnology Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Sana Biotechnology Inc for 23 Days on average.
| IRM | SANA | |
|---|---|---|
Market Cap | $34.46B | $836.71M |
Volume | 1,379,608 | 4,507,444 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $5.92 |
52-Week Low | $78.86 | $2.68 |
Typical Hold Time | 80 Days | 23 Days |
Enterprise Value | $53.87B | $749.96M |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $114.51, down 1.05% on the day, with a bearish technical signal and elevated valuation metrics like a P/E of 82.09. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.60 surpassing the $0.543 forecast. The company is expanding its data center pipeline and digital solutions, targeting 300MW capacity, while revenue grew to $6.90 billion in 2025. However, net income margin has declined to 2.09%, and debt-to-asset ratio rose to 79.04% in 2025, indicating financial leverage concerns.
The outlook is mixed: strong analyst consensus with a $142.75 price target and 66.7% buy ratings support upside potential, but high debt, margin pressure, and bearish technicals pose risks. Growth in data centers and digital services offers opportunity, yet investors must weigh leverage and profitability trends against expansion prospects.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
